BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 7749985)

  • 1. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency.
    Zhou H; Glimcher LH
    Immunity; 1995 May; 2(5):545-53. PubMed ID: 7749985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome).
    Steimle V; Otten LA; Zufferey M; Mach B
    Cell; 1993 Oct; 75(1):135-46. PubMed ID: 8402893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant.
    Zhou H; Su HS; Zhang X; Douhan J; Glimcher LH
    J Immunol; 1997 May; 158(10):4741-9. PubMed ID: 9144488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.
    Sartoris S; Tosi G; De Lerma Barbaro A; Cestari T; Accolla RS
    Eur J Immunol; 1996 Oct; 26(10):2456-60. PubMed ID: 8898960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex.
    Masternak K; Muhlethaler-Mottet A; Villard J; Zufferey M; Steimle V; Reith W
    Genes Dev; 2000 May; 14(9):1156-66. PubMed ID: 10809673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation.
    Masternak K; Reith W
    EMBO J; 2002 Mar; 21(6):1379-88. PubMed ID: 11889043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation in the class II trans-activator leading to a mild immunodeficiency.
    Wiszniewski W; Fondaneche MC; Le Deist F; Kanariou M; Selz F; Brousse N; Steimle V; Barbieri G; Alcaide-Loridan C; Charron D; Fischer A; Lisowska-Grospierre B
    J Immunol; 2001 Aug; 167(3):1787-94. PubMed ID: 11466404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Degradation, Promoter Recruitment and Transactivation Mediated by the Extreme N-Terminus of MHC Class II Transactivator CIITA Isoform III.
    Beaulieu YB; Leon Machado JA; Ethier S; Gaudreau L; Steimle V
    PLoS One; 2016; 11(2):e0148753. PubMed ID: 26871568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conserved residues of the bare lymphocyte syndrome transcription factor RFXAP determine coordinate MHC class II expression.
    Long AB; Ferguson AM; Majumder P; Nagarajan UM; Boss JM
    Mol Immunol; 2006 Feb; 43(5):395-409. PubMed ID: 16337482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter.
    Deffrennes V; Vedrenne J; Stolzenberg MC; Piskurich J; Barbieri G; Ting JP; Charron D; Alcaïde-Loridan C
    J Immunol; 2001 Jul; 167(1):98-106. PubMed ID: 11418637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of MHC class II gene expression in a patient with a single amino acid substitution in the class II transactivator protein CIITA.
    Quan V; Towey M; Sacks S; Kelly AP
    Immunogenetics; 1999 Oct; 49(11-12):957-63. PubMed ID: 10501838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.
    Lu HT; Riley JL; Babcock GT; Huston M; Stark GR; Boss JM; Ransohoff RM
    J Exp Med; 1995 Nov; 182(5):1517-25. PubMed ID: 7595221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of class II transcriptional activator-induced genes by representational difference analysis: discoordinate regulation of the DN alpha/DO beta heterodimer.
    Taxman DJ; Cressman DE; Ting JP
    J Immunol; 2000 Aug; 165(3):1410-6. PubMed ID: 10903745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective MHC class II expression in an MHC class II deficiency patient is caused by a novel deletion of a splice donor site in the MHC class II transactivator gene.
    Peijnenburg A; Van den Berg R; Van Eggermond MJ; Sanal O; Vossen JM; Lennon AM; Alcaïde-Loridan C; Van den Elsen PJ
    Immunogenetics; 2000 Jan; 51(1):42-9. PubMed ID: 10663561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA).
    Riley JL; Westerheide SD; Price JA; Brown JA; Boss JM
    Immunity; 1995 May; 2(5):533-43. PubMed ID: 7749984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5.
    Scholl T; Mahanta SK; Strominger JL
    Proc Natl Acad Sci U S A; 1997 Jun; 94(12):6330-4. PubMed ID: 9177217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An isotype-specific activator of major histocompatibility complex (MHC) class II genes that is independent of class II transactivator.
    Douhan J; Lieberson R; Knoll JH; Zhou H; Glimcher LH
    J Exp Med; 1997 Jun; 185(11):1885-95. PubMed ID: 9166418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of major histocompatibility complex class II gene expression and demonstration of antigen-specific T cell response indicate a new phenotype in class II-deficient patients.
    Hauber I; Gulle H; Wolf HM; Maris M; Eggenbauer H; Eibl MM
    J Exp Med; 1995 Apr; 181(4):1411-23. PubMed ID: 7699327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of human anti-porcine T-cell immune responses by major histocompatibility complex class II transactivator constructs lacking the amino terminal domain.
    Yun S; Gustafsson K; Fabre JW
    Transplantation; 1998 Jul; 66(1):103-11. PubMed ID: 9679829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CIITA-induced occupation of MHC class II promoters is independent of the cooperative stabilization of the promoter-bound multi-protein complexes.
    Villard J; Muhlethaler-Mottet A; Bontron S; Mach B; Reith W
    Int Immunol; 1999 Mar; 11(3):461-9. PubMed ID: 10221658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.